The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
At least 7 weeks since completion of DE 4, surely the next one is due soon hopefully with access to the full plan to complete P1A, less than 4 months til mid year. Clearly we aren’t going to anything under 250… 300 + coming?
One things that’s known is that in 5 weeks will have a full science day, where AS & co will be providing a full up of the therapeutics division of the business. The P1a update will come between now and then. Stay positive REAL holders, if this goes as we expect the odd day or 2 wait for updates won’t mean anything. Imagine being on the team who want this improvement in cancer treatment to fail, strange how type of humans.
My take is that we will get an RNS in the next 10
Market days to confirm completion of cohort 4 and that all data in now in review to support start of phase 1b. We will then get confirmation of an open day, which surely needs at least 1 weeks notice for people to attend. Around about the time of the open day we will get the final data package for 1a. It will either be doors blown off or barricaded….. surely has to be the first one or the CEO will take another big hit to the ego.
Neil Bell, Chief Development Officer, Avacta
Neil has over 30 years’ experience in the drug development industry, having held senior positions in global pharmaceutical companies and innovative biotechs. The early part of his career was spent in clinical development at Eisai and Pfizer before becoming Therapeutic Area Head for Gastroenterology and Neurology at Ipsen. In each of these roles he led numerous Phase I to III clinical studies, gaining significant experience across all facets of drug development; from strategy to pre-clinical development, manufacturing and regulatory, to clinical study design and implementation.
In his role as Head of Global Clinical Operations for Teva Pharmaceuticals, Neil led an international team responsible for the delivery of clinical programmes in neurology, autoimmune and oncology therapeutic areas. During this period, he contributed to the development of Copaxone achieving leadership in the treatment for multiple sclerosis globally, as well as successfully introducing Azilect to global markets.
Following this period at Teva, Neil joined Daichi-Sankyo as Head of Clinical Operations where he led the clinical operations team through early and late stage development activities across cardiovascular, pain and oncology, and was responsible for building an effective drug development organisation in Europe serving the global clinical programmes and leading to the successful global approval of Edoxaban.
Most recently, Neil held the role of Senior Vice President, Head of Global Clinical Operations at Autolus, a UK cell and gene therapy company backed by Syncona, which listed in the US in 2018; a process in which Neil played a key role. At Autolus Neil was responsible for building a fully functional global clinical operations team delivering Phase I/II clinical studies across the UK, Europe and US in acute lymphoblastic leukemia, multiple myeloma, B-cell lymphoma, and T-cell lymphoma, and implemented the first commercially sponsored CAR-T study in the UK.
I know we all want AS to keep quiet, but with the battering the SP is taking is it not time for communication with a full and detailed business update. Starting with the LFT. If it’s gone then be honest and say it’s gone. Not like it’s going to negatively impact the SP. What is the Wetherby team doing at the moment? They must be working on something.
Also are they allowed to discuss the current SP in and RNS or interview. Be honest and frank with us investors, can they mention shorts etc? With the price dropping by 60% in 7weeks and all we get is a forced and miserable interview with Vox. No other comments. If this was my company the only reason I’d stay quiet is because I can’t defend myself… sorry for the rant…gla
https://youtu.be/RgWQCGX3MOk
Not that interesting to most, but good simple explanation to chemo and shows how ava6000 will hopefully help.
For me there are still a lot of people with their eye on Avacta, be it PIs and hopefully IIs too!
It’s obvious shorters are in charge right now, led by Jupiter but backed by many PIs who are pushing the negative message to try and get more and more PIs to sell and drive the price lower.
There must be a lot of people sat watching daily SP movements(not just current PIs) who are looking for a change in sentiment and visibility of shorts being closed. I believe (maybe wishful thinking) that once this occurs people will being to show their hand more and more and the SP will begin its recovery prior to mid year ground breaking news.
Although it’s very very hard for holders to watch, the more the SP drops the more chance it’s give us to average down and we won’t then need to see £2+ to at least get back to ground zero.
Very hard times but patient investors will be rewarded, its either that or nothing works and AS and crew won’t have a company left!
GLA
Changing the subject….. I’m sure this won’t happen and have every confidence in AS and especially Neil Bell, but let’s just say the dose escalation isn’t successful( what ever reason) does that mean we can just go back to 90% if that is working well and expand the patient review to prove up the drug to go to market. Surely a safer drug even at 90% dose still beats the current drug in use? People have been saying for along time this isn’t like other drug trials it either works or it doesn’t it’s just about finding the correct does amount etc…sure im wrong and prepared to be called a fool! Thanks
I have read through historic chats and RNS but can’t find the answer. Is there a reason we have only starting recruiting/dosing at 3 hospitals in the uk. Are the other 3 part of the dose escalation phase or phase 2? Or do we simply not know at this stage. Thanks
NAROD just a LTH trying to build up my knowledge.
Imagine AS making an opening statement at the II meeting.
“So we spent millions of pounds and 20mths trying to get an LFT to market, well we have withdrawn that from sale now. Also our main market is The precision platform and Ava6000 is on clinic. Sadly that isn’t working very well, but we’d like to keep trying other drugs and need your investment to do it, so how many shares would you like?”
It’s can’t happen! Ava6000 must be going well!!!!
Id say almost certainly not. Let’s say we release great news and the SP by some miracle goes to £2+. Why would IIS be keen to jump on board when 2 days previous they could buy at 85p. Surely they will be selling the story at a low price with the promise of investing to win more money.
Can I ask what I’m sure is a stupid question. There has been talk of the new consultants coming on board and new investor seminars etc to push for new money coming into the business.However, if AS and crew have sight of positive data for AVA6000, why do we need a push for new investors, wouldn’t we expect them to be beating down our doors if that’s the case? Which believe me for many reasons I really really hope it is! Not being negative just trying to put my mind at rest (a little) Thanks LTH